Newsgroup: it.economia.borsa
Titolo: AH AH AH AH AH AH AH AH AH AH da preda a predatore??

tutti ad aspettare che Cell fosse acquistata...
e invece è Cell che si mette pure ad acquistare
ma come fa?? emetterà azioni?? ha dietro qualcuno??? chi ci capisce...
adesso tutti a chiedersi come prenderà il mercato la notizia luned' (cmq non 
sembrerebbe una cosa negativa, dovrebbe essere un buon segno...)
daje mascherò, come il Carter dei TNT
EBBENE SI: HAI VINTO ANCHE STAVOLTA :-))
============================================
DOR BioPharma Receives Unsolicited Acquisition Proposal From Cell 
Therapeutics
Jan 19 2007, 12:40 PM EST
MARKETWIRE
Jan 19, 2007 MIAMI, FL MARKET WIRE
DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company") announced today 
that it has received an unsolicited proposal from Cell Therapeutics, Inc. 
("Cell Therapeutics") to acquire DOR.
Under the proposed terms, Cell Therapeutics would issue the Company's 
shareholders 29,000,000 shares of Cell Therapeutics' common stock, 
representing 19.9% of Cell Therapeutics' outstanding shares of common stock. 
Warrant and option holders would receive shares of Cell Therapeutics' common 
stock in an amount determined using the Black Scholes pricing model. Cell 
Therapeutics has reserved the right to offer cash as consideration for the 
warrants instead of Cell Therapeutics' common stock. In addition, Cell 
Therapeutics is also offering the potential for an additional $15 million 
payment (in stock or cash at the Company's option) upon receipt of the 
approval of the U.S. Food & Drug Administration of the Company's new drug 
application for orBec(R). The proposal from Cell Therapeutics is subject to, 
among other things, the completion of satisfactory due diligence regarding 
clinical, regulatory, manufacturing and proprietary positioning for 
orBec(R).
As previously announced on January 3, 2007, the Company entered into a 
non-binding letter of intent (the "Letter of Intent") with Sigma-Tau 
Pharmaceuticals, Inc. ("Sigma-Tau"), which grants Sigma-Tau an exclusive 
right to negotiate terms and conditions for a possible business transaction 
or strategic alliance regarding the Company's lead product, orBec(R), and 
potentially other Company programs until March 1, 2007. Accordingly, absent 
express written permission from Sigma-Tau, the Company's board of directors 
cannot consider Cell Therapeutics' merger proposal at this time.
A copy of the Cell Therapeutics' January 17, 2007 proposal is filed as an 
Exhibit to the Form 8-K filed today January 19, 2007.
About DOR BioPharma, Inc.
DOR BioPharma, Inc. is a biopharmaceutical company developing products to 
treat life-threatening side effects of cancer treatments and serious 
gastrointestinal diseases, and vaccines for certain bioterrorism agents. 
DOR's lead product, orBec(R) (oral beclomethasone dipropionate), is a 
potent, locally acting corticosteroid being developed for the treatment of 
GI GVHD, a common and potentially life-threatening complication of bone 
marrow transplantation. DOR has filed an NDA with the FDA for the treatment 
of GI GVHD, and has received an FDA PDUFA date of July 21, 2007. An MAA with 
the EMEA for orBec(R) has also been filed and validated. orBec(R) may also 
have application in treating other gastrointestinal disorders characterized 
by severe inflammation.
Through its Biodefense Division, DOR is developing biomedical 
countermeasures pursuant to the recently enacted Project BioShield Act of 
2004. DOR's biodefense products in development are recombinant subunit 
vaccines designed to protect against the lethal effects of exposure to ricin 
toxin and botulinum toxin. The ricin toxin vaccine, RiVax(TM), has been 
evaluated successfully in a Phase 1 clinical trial in normal volunteers.
For further information regarding DOR BioPharma, please visit the Company's 
website located at 
www.dorbiopharma.com
.
This press release contains forward-looking statements, within the meaning 
of Section 21E of the Securities Exchange Act of 1934, that reflect DOR 
BioPharma, Inc.'s current expectations about its future results, 
performance, prospects and opportunities, including statements regarding the 
potential use of orBec(R) for the treatment of gastrointestinal GVHD and the 
prospects for regulatory filings for orBec(R). Where possible, DOR has tried 
to identify these forward-looking statements by using words such as 
"anticipates," "believes," "intends," or similar expressions. These 
statements are subject to a number of risks, uncertainties and other factors 
that could cause actual events or results in future periods to differ 
materially from what is expressed in, or implied by, these statements. DOR 
cannot assure you that it will be able to successfully develop or 
commercialize products based on its technology, including orBec(R), 
particularly in light of the significant uncertainty inherent in developing 
vaccines against bioterror threats, manufacturing and conducting preclinical 
and clinical trials of vaccines, and obtaining regulatory approvals, that 
its technologies will prove to be safe and effective, that its cash 
expenditures will not exceed projected levels, that it will be able to 
obtain future financing or funds when needed, that product development and 
commercialization efforts will not be reduced or discontinued due to 
difficulties or delays in clinical trials or due to lack of progress or 
positive results from research and development efforts, that it will be able 
to successfully obtain any further grants and awards, maintain its existing 
grants which are subject to performance, enter into any biodefense 
procurement contracts with the U.S. Government or other countries, that the 
U.S. Congress may not pass any legislation that would provide additional 
funding for the Project BioShield program, that it will be able to patent, 
register or protect its technology from challenge and products from 
competition or maintain or expand its license agreements with its current 
licensors, or that its business strategy will be successful. Important 
factors which may affect the future use of orBec(R) for gastrointestinal 
GVHD include the risks that: because orBec(R) did not achieve statistical 
significance in its primary endpoint in the pivotal Phase 3 clinical study 
(i.e. a p-value of less than or equal to 0.05), the FDA may not consider 
orBec(R) approvable based upon existing studies, orBec(R) may not show 
therapeutic effect or an acceptable safety profile in future clinical 
trials, if required, or could take a significantly longer time to gain 
regulatory approval than DOR expects or may never gain approval; DOR is 
dependent on the expertise, effort, priorities and contractual obligations 
of third parties in the clinical trials, manufacturing, marketing, sales and 
distribution of its products; or orBec(R) may not gain market acceptance; 
and others may develop technologies or products superior to orBec(R). There 
can be no assurance that neither the unsolicited proposed from Cell 
Therapeutics nor a transaction with Sigma-Tau will be realized. These and 
other factors are described from time to time in filings with the Securities 
and Exchange Commission, including, but not limited to, DOR's most recent 
reports on Form 10-QSB and Form 10-KSB. DOR assumes no obligation to update 
or revise any forward-looking statements as a result of new information, 
future events, and changes in circumstances or for any other reason. 

e pochi giorni fa la stessa DOR aveva ricevuto una offerta da parte di 
Sigma-TAu......
January 4 , 2007
DOR BioPharma Receives $3 Million from Sigma-Tau Pharmaceuticals for 
Exclusive Right to Negotiate orBecŽ Strategic Alliance.
intanto stasera DOR chiude a +80.33%
DOR dovevamo prendere intanto,  no CELL hi hi ih :-))

firmi tu le cambialette ??? 

 firmi tu le cambialette ???
è solo un'offerta e potrebbero rifiutare, anche se c'è puzza di bruciato sul 
solo fatto che venga fatta una offerta simile da parte di una società che ha 
soldi si e no per altri sei mesi;
le cambialette quindi le firmerà forse Novartis, forse Pfizer, forse la 
stessa Sigma (che alla fine Dor se la compra lo stesso, ma attraverso Cell: 
acquistare debiti fa sempre comodo ai fini fiscali... capito caro 
Peter.....????)
e le tue medie mobili, e i tuoi martelli??? :-P 

 shareholders 29,000,000 shares of Cell Therapeutics' common stock,
Certo che siete stupendi voi.
29 milioni di pezzi di nuova carta Cell sul mercato me lo chiami "buon 
segno" ?
Io la chiamo l'ennesima trombata a danno degli azionisti Cell.
-- 
"Mi interessa il futuro, perchč č lě che vivrň il resto della mia vita."
(Woody Allen) 

di niubbi ???
ancora ????